NovaDel has a robust pipeline of drug candidates in all stages of development, with one approved product in the U.S., one with an NDA under review by the FDA, and multiple candidates in earlier stages of development and clinical review.

NovaDel’s pipeline is composed entirely of oral spray drug candidates that were generated through the application of the Company’s proprietary oral spray NovaMist™ technology to currently approved pharmaceuticals.  This technology enables more rapid delivery of drugs into the bloodstream potentially resulting in faster onset of action and patient benefits in compliance, convenience and safety.